Aimspro: Phase IIa data

A double-blind, placebo-controlled Phase IIa trial in 20 patients with diffuse systemic sclerosis showed that twice-weekly 4.5 mg/mL subcutaneous Aimspro for 26 weeks was well tolerated with no deteri...